NewAmsterdam Pharma Company N.V. Labor and Related Expense
NewAmsterdam Pharma Company N.V. (NAMS) reported Labor and Related Expense of $12.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LaborAndRelatedExpense · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. labor and related expense for the quarter ending 2026-06-30 was $12.66M, a 27.85% increase year-over-year.
- NewAmsterdam Pharma Company N.V. labor and related expense for the quarter ending 2026-03-31 was $11.79M, a 16.03% increase year-over-year.
- NewAmsterdam Pharma Company N.V. labor and related expense for the quarter ending 2025-12-31 was $10.37M, a 14.71% decline year-over-year.
- NewAmsterdam Pharma Company N.V. labor and related expense for the quarter ending 2025-09-30 was $10.35M, a 15.76% increase year-over-year.
- NewAmsterdam Pharma Company N.V. labor and related expense for fiscal 2025 was $40.79M, a 22.15% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. labor and related expense for fiscal 2024 was $33.39M, a 130.68% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. labor and related expense for fiscal 2023 was $14.47M, a 104.83% increase from fiscal 2022.
- NewAmsterdam Pharma Company N.V. labor and related expense for fiscal 2022 was $7.07M.
| Period end | Labor and Related Expense 3 month | Labor and Related Expense 6 month | Labor and Related Expense 9 month | Labor and Related Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.66M 10-Q · filed 2026-08-05 | $24.45M 10-Q · filed 2026-08-05 | $34.82M derived: sum of 3 quarters · filed 2026-08-05 | $45.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $11.79M 10-Q · filed 2026-05-07 | $22.16M derived: sum of 2 quarters · filed 2026-05-07 | $32.52M derived: sum of 3 quarters · filed 2026-05-07 | $42.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $10.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $20.73M derived: sum of 2 quarters · filed 2026-02-18 | $30.63M derived: sum of 3 quarters · filed 2026-08-05 | $40.79M 10-K · filed 2026-02-18 |
| 2025-09-30 | $10.35M 10-Q · filed 2025-11-05 | $20.25M derived: sum of 2 quarters · filed 2026-08-05 | $30.41M 10-Q · filed 2025-11-05 | $42.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $9.90M 10-Q · filed 2026-08-05 | $20.06M 10-Q · filed 2026-08-05 | $32.23M derived: sum of 3 quarters · filed 2026-08-05 | $41.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $10.16M 10-Q · filed 2026-05-07 | $22.32M derived: sum of 2 quarters · filed 2026-05-07 | $31.27M derived: sum of 3 quarters · filed 2026-05-07 | $38.28M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $21.11M derived: sum of 2 quarters · filed 2026-02-18 | $28.12M derived: sum of 3 quarters · filed 2026-02-18 | $33.39M 10-K · filed 2026-02-18 |
| 2024-09-30 | $8.94M 10-Q · filed 2025-11-05 | $15.96M derived: sum of 2 quarters · filed 2025-11-05 | $21.23M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $7.02M 10-Q · filed 2025-08-06 | $12.29M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $5.27M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $14.47M 10-K · filed 2026-02-18 | |||
| 2022-12-31 | $7.07M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |